Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rang in Aktien #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Aktienkurs
$22.26
Zuletzt synchronisiert: 2024-03-22
Marktkapitalisierung
$553.40M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Graphite Bio, Inc. (GRPH)

Kategorie

Aktien-Split-Historie für Graphite Bio, Inc. (GRPH)
Die Aktie Graphite Bio, Inc. (Symbol: GRPH) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 31, 2026 statt.
Eine GRPH-Aktie, die vor dem Aug 31, 2026 gekauft wurde, entspricht heute 0 GRPH-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH